PSC Drug Pipeline: FXR & PPAR Agonists — PatSnap Eureka
Primary Sclerosing Cholangitis: FXR Agonists, PPAR Agonists & Biliary Fibrosis Approaches
No approved disease-modifying therapy exists for PSC. Explore the patent-driven pipeline spanning FXR agonists, PPAR agonists, integrin inhibitors, anti-CLDN1 biologics, and ASBT inhibitors — mapped across 10+ assignees and 6 mechanistic axes using PatSnap Eureka.
A Rare Cholestatic Disease With No Approved Cure
Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease characterized by periductal fibrosis, progressive biliary stricturing, and an eventual trajectory toward end-stage liver disease, cholangiocarcinoma, and liver transplantation. According to WHO rare disease classifications, PSC affects a small but high-burden patient population with limited treatment options globally.
PSC involves complex, multifactorial causation including genetic susceptibility, immune dysregulation, and potentially gut-liver axis disruption. The disease's strong comorbidity with inflammatory bowel disease — present in 70–80% of patients — compounds therapeutic urgency and complicates trial design.
Current first-line treatment with ursodeoxycholic acid (UDCA) shows limited efficacy in PSC. Approximately 30–40% of PBC patients on UDCA do not achieve adequate biochemical response, and PSC patients show even more limited UDCA efficacy. Liver transplantation remains the only curative option — creating a durable commercial opportunity for any agent demonstrating slowing of fibrotic progression or cholestasis reduction in clinical trials.
The NIH and academic centers including the Medical University of Vienna have characterized the TH17/Treg imbalance in PSC as a key immunological driver, with NorUDCA (24-nor-ursodeoxycholic acid) shown to counteract this imbalance by restricting glutaminolysis in differentiating TH17 cells — a mechanism distinct from UDCA's bicarbonate umbrella effects.
Six Mechanistic Axes Targeting PSC
The PSC pipeline spans bile acid receptor agonism, PPAR activation, integrin inhibition, biologic targeting of CLDN1, bile acid transporter blockade, and immunological approaches — reflecting active mechanistic diversification.
FXR Agonists (NR1H4)
The largest cluster in this dataset. FXR activation suppresses CYP7A1-mediated bile acid synthesis via the FGF19/FXR signaling cascade, reducing hepatotoxic bile acid accumulation. Multiple patent filings from Gilead Sciences, Intercept Pharmaceuticals, Novartis, Metacrine, and Organovo/Metacrine reference FXR as the central target. Obeticholic acid (OCA) is approved for PBC, providing clinical precedent for the mechanism in closely related cholestatic disease.
7 distinct assignees · Steroidal & non-steroidalPPAR Agonists (α/δ/γ)
Peroxisome proliferator-activated receptors are cited as targets for cholestatic and fibrotic liver disease. Elafibranor (PPAR-α/δ dual agonist, Genfit) explicitly listed for PSC and PBC. Lanifibranor (pan-PPAR agonist, Inventiva) described in 2025 WO filing for autoimmune cholangitis prevention. T3D Therapeutics describes PPAR-δ/γ dual agonists with PSC listing. Mirum Pharmaceuticals positions seladelpar, bezafibrate, elafibranor, and fenofibrate as ASBT inhibitor combination partners.
4 assignees · Dual & pan-PPAR strategiesαvβ6/αvβ1 Integrin Inhibitors
Pliant Therapeutics holds two recently filed patents (WO 2025, US 2025) covering a selective αvβ6/αvβ1 integrin inhibitor (quinazolinylamino-butanoic acid derivative) for PSC. These integrins act as profibrotic mediators by activating TGF-β signaling — a critical driver of periductal biliary fibrosis. Optional co-administration with UDCA positions this as a combination-ready anti-fibrotic mechanism. This represents the most PSC-specific, recently filed small molecule IP in this dataset.
Pliant Therapeutics · WO & US 2025 · TGF-β axisAnti-Claudin-1 (CLDN1) Antibodies
Alentis Therapeutics AG has filed patents in multiple jurisdictions (WO 2023, AU/JP/CN 2025) for anti-CLDN1 monoclonal antibodies directed at PSC and PBC. CLDN1 is a transmembrane tight junction protein expressed non-junctionally in cholangiopathies. In the DDC mouse model, anti-CLDN1 mAb treatment (25 mg/kg, weekly, 3 weeks) resulted in decreased plasma alkaline phosphatase and reduced periductal fibrosis (Sirius red staining). This mechanism is orthogonal to all bile acid and metabolic approaches in this dataset.
Alentis Therapeutics · In vivo PoC data · First-in-classASBT Inhibitors
Lumena Pharmaceuticals filed patents across WO, EP, CA, and AU (2014–2016) for ASBT inhibitors targeting PSC and IBD. The mechanism prevents ileal reabsorption of bile acids, reducing the hepatic bile acid load driving biliary toxicity and fibrosis. Mirum Pharmaceuticals subsequently filed for ASBT inhibitor compositions (maralixibat) with PPAR agonist combination strategies for cholestatic liver disease — combining bile acid recycling blockade with anti-inflammatory PPAR activity.
Lumena & Mirum · PSC + IBD co-targetingImmune Cell Trafficking & NorUDCA
Millennium Pharmaceuticals describes vedolizumab-class humanized anti-α4β7 antibody for PSC, targeting immune cell trafficking to the biliary tract. A 2012 WO patent describes apheresis to remove CCR9/CXCR4/CCR7/CCR5-expressing immune cells from PSC patient peripheral blood. Academic literature from the Medical University of Vienna establishes NorUDCA's immunomodulatory mechanism via metabolic reprogramming of T cells — restricting glutaminolysis required for TH17 differentiation in PSC models.
Anti-α4β7 · Apheresis · NorUDCA TH17/Treg axisPatent Activity & IP Landscape Signals
Key data points derived from patent filing analysis via PatSnap Eureka across the PSC therapeutic pipeline.
Intercept Pharmaceuticals: FXR+Fibrate IP Geographic Footprint
Intercept holds the broadest geographic patent portfolio for FXR agonist + fibrate combinations targeting cholestatic liver disease — at minimum 8 jurisdiction records in this dataset.
PSC Combination Therapy Strategies: Mechanistic Axes
Eight distinct combination approaches are documented in the dataset, with FXR + PPAR (fibrate) being the dominant pairing across multiple independent assignees.
Commercial IP Leaders in the PSC Pipeline
Activity is strongly patent-driven. The following assignees represent the leading IP positions by filing volume and geographic spread in this dataset.
Track PSC Patent Activity in Real Time
Set alerts for new FXR, PPAR, integrin, and CLDN1 filings across all jurisdictions with PatSnap Eureka.
What the PSC Patent Landscape Signals
Key strategic takeaways derived from patent filing patterns, assignee activity, and mechanistic diversification across the PSC pipeline dataset.
FXR Agonism: Dense IP Landscape
FXR agonism remains the dominant IP axis for cholestatic liver disease in this dataset, with Intercept Pharmaceuticals holding the broadest geographic portfolio and Gilead, Metacrine, and Novartis representing competitive chemistry-IP positions. Any entrant into this space must navigate a dense FXR patent landscape, particularly for cholestatic indications.
Combination IP Filing Is Now a Core Strategy
PPAR agonists — especially elafibranor (Genfit) and lanifibranor (Inventiva) — are emerging as leading PPAR-axis candidates for PSC, with combination strategies (PPAR + FXR, PPAR + ACC inhibitor, PPAR + GLP-1) providing freedom-to-operate differentiation and potential for superior efficacy over monotherapy.
From Preclinical Models to Clinical Precedent
Retrieved results contain limited but informative translational signals. No retrieved results explicitly describe completed Phase 3 data, regulatory submissions, or approved agents specifically for PSC — underscoring the scale of the remaining unmet need documented across EMA and FDA rare disease frameworks.
Elafibranor (Genfit) — Retrieved patent text explicitly references a completed Phase 2b NASH trial (GFT505-212-7, 1-year, liver biopsy-based) as clinical precedent for the compound, supporting translational maturity, though the specific PSC indication is not described as having reached clinical endpoints in the retrieved data.
Obeticholic acid (OCA) — Multiple retrieved patent texts reference OCA's approved status for PBC in the United States (as of 2016), contextualizing FXR agonism as a mechanism with demonstrated clinical validation in closely related cholestatic disease. Retrieved text notes approximately 30–40% of PBC patients on UDCA do not achieve adequate biochemical response, establishing the patient population rationale for next-generation FXR agents.
Anti-CLDN1 antibody (Alentis Therapeutics) — Retrieved WO patent describes in vivo proof-of-concept in the DDC mouse PSC model with quantitative pharmacodynamic data: plasma alkaline phosphatase reduction and Sirius red fibrosis scoring — establishing IND-enabling preclinical activity consistent with early clinical translation stage. Learn more about life sciences patent intelligence for biologic drug programs.
NorUDCA — Retrieved academic literature from the Medical University of Vienna describes mechanistic studies in both the Mdr2−/− mouse model of PSC and adoptive transfer colitis models, providing translational mechanistic support for TH17/Treg rebalancing via glutaminolysis restriction.
PSC Drug Pipeline — Key Questions Answered
Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease characterized by periductal fibrosis, progressive biliary stricturing, and an eventual trajectory toward end-stage liver disease, cholangiocarcinoma, and liver transplantation — with no approved pharmacological disease-modifying therapy to date. PSC involves complex, multifactorial causation including genetic susceptibility, immune dysregulation, and potentially gut-liver axis disruption.
FXR activation suppresses CYP7A1-mediated bile acid synthesis via the FGF19/FXR signaling cascade, reducing hepatotoxic bile acid accumulation in cholestatic disease. FXR agonism is proposed to: (1) suppress bile acid synthesis via CYP7A1 downregulation and FGF19 upregulation; (2) reduce hepatic inflammation; (3) inhibit hepatic stellate cell activation and fibrogenesis.
Two distinct PPAR agonist strategies are documented for cholestatic liver disease including PSC: elafibranor (a PPAR-α/δ dual agonist from Genfit), and lanifibranor (a pan-PPAR agonist from Inventiva). T3D Therapeutics also describes PPAR-δ/γ dual agonists with explicit PSC listing among indications. Mirum Pharmaceuticals positions PPAR agonists including seladelpar, bezafibrate, elafibranor, and fenofibrate as combination partners with ASBT inhibitors for pediatric cholestatic liver disease.
Alentis Therapeutics AG identifies CLDN1, a transmembrane tight junction protein expressed non-junctionally in cholangiopathies, as a target for PSC. In the DDC mouse model of PSC, anti-CLDN1 monoclonal antibody treatment (25 mg/kg, weekly, 3 weeks) resulted in decreased plasma alkaline phosphatase and reduced periductal fibrosis (Sirius red staining). The mechanism of action is described as targeting CLDN1-mediated cholangiocyte plasticity and fibrogenic signaling.
Retrieved results reveal a strong combinatorial trend: FXR agonist + PPAR agonist (fibrate) is the dominant combination strategy. Other combinations include FXR agonist + ACC inhibitor, PPAR agonist + ACC inhibitor, FXR agonist + SSAO inhibitor, ASBT inhibitor + PPAR agonist, lanifibranor + GLP-1/glucagon dual agonist, and integrin inhibitor + UDCA. These combinations target complementary mechanisms including bile acid metabolism, inflammation, fibrosis, and lipid metabolism simultaneously.
There is no approved pharmacological disease-modifying therapy for PSC to date. Current first-line treatment with ursodeoxycholic acid (UDCA) shows limited efficacy in PSC. Approximately 30–40% of PBC patients on UDCA do not achieve adequate biochemical response, and PSC patients show even more limited UDCA efficacy. Liver transplantation remains the only curative option, creating a durable commercial opportunity for any agent demonstrating slowing of fibrotic progression or cholestasis reduction in clinical trials.
Still have questions about PSC drug targets or patent strategies? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About PSCAccelerate Your PSC Drug Discovery & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Map FXR, PPAR, integrin, and biologic IP in the PSC space — from target identification to freedom-to-operate analysis.
References
- Integrin inhibitors for treatment of primary sclerosing cholangitis — Pliant Therapeutics, Inc., 2025, WO [Patent]
- Integrin inhibitors for treatment of primary sclerosing cholangitis — Pliant Therapeutics, Inc., 2025, US [Patent]
- Novel FXR (NR1H4) binding and activity modulating compounds — Gilead Sciences, Inc., 2017, ES [Patent]
- Novel FXR (NR1H4) binding and activity modulating compounds — Gilead Sciences, Inc., 2016, ES [Patent]
- Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease — Intercept Pharmaceuticals, Inc., 2021, SG [Patent]
- Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease — Intercept Pharmaceuticals, Inc., 2020, CA [Patent]
- Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease — Intercept Pharmaceuticals, Inc., 2022, US [Patent]
- Treatment of fibrosis using FXR ligands — Intercept Pharmaceuticals, Inc., 2006, AU [Patent]
- Farnesoid x receptor agonists for the treatment of disease — Metacrine, Inc., 2021, WO [Patent]
- Farnesoid x receptor agonists for the treatment of disease — Metacrine, Inc., 2023, US [Patent]
- Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor — Genfit, 2022, IL [Patent]
- Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor — Genfit, 2019, IL [Patent]
- Combination therapy for the prevention and/or the treatment of a liver disease — Inventiva, 2025, WO [Patent]
- Methods of treating liver disease using indane acetic acid derivatives — T3D Therapeutics, Inc., 2016, CA [Patent]
- Use of Anti-claudin-1 antibodies to treat cholangiopathies — Alentis Therapeutics AG, 2023, WO [Patent]
- Use of an anti-Claudin-1 antibody for treating cholangiopathy — Alentis Therapeutics AG, 2025, JP [Patent]
- Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease — Lumena Pharmaceuticals, Inc., 2014, WO [Patent]
- Apical sodium-dependent transporter inhibitor compositions — Mirum Pharmaceuticals, Inc., 2023, CA [Patent]
- Method of treating primary sclerosing cholangitis — Millennium Pharmaceuticals, Inc., 2016, CA [Patent]
- 24-Nor-ursodeoxycholic acid counteracts TH17/Treg imbalance and ameliorates intestinal inflammation by restricting glutaminolysis in differentiating TH17 cells — Medical University of Vienna, 2022 [Paper]
- World Health Organization — Rare Diseases
- National Institutes of Health — Liver Disease Research
- European Medicines Agency — Orphan Medicines
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.